Life Sciences & Medicine Active Updated Nov 16, 2026
Stem cells with a bone-marrow address for osteoporosis
Where it stands as of Nov 16, 2026
A first-in-human trial in Cell gave ten women over 50 with advanced osteoporosis a single infusion of their own stem cells coated in a sugar that steers them to bone marrow. Fractures across the group fell from an average of eight per year to 0.5 per year over two years. Ten patients is a very small group, there was no control arm described, and where the cells went after infusion was not tracked.
The story so far
-
Nov 16, 2026 Latest
A first-in-human trial in Cell gave ten women over 50 with advanced osteoporosis one infusion of their own mesenchymal stem cells coated in a sugar that acts as a return address for bone marrow. Fractures fell from an average of eight per year to 0.5 per year over two years, bone-tissue area rose about 70 percent at four months, and patients reported 34 percent less bone pain. Co-author Robert Sackstein holds intellectual-property rights to the cell-engineering technology.
This story moves with the morning letter.
When this question gets a new answer, the page above changes the same morning. Each morning's letter brings the day's progress in science, medicine and beyond. Free, every day.
Free for good. One click to leave.